Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mini-Sentinel Safety Review Of Xarelto Expands FDA’s Scrutiny Of Anticoagulants

This article was originally published in The Pink Sheet Daily

Executive Summary

The postmarket safety assessment of J&J/Bayer’s Xarelto will use Mini-Sentinel’s Prospective Routine Observational Monitoring Programming Tools surveillance system, a new program that can track new drugs as they enter the market on an ongoing, semi-automated basis.

You may also be interested in...

FDA Scales Back Near-Term Goals For Sentinel Postmarket Data Network

FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.

Pradaxa Bleeding Risk Gets Deeper FDA Scrutiny In Mini-Sentinel Project

A 2012 Sentinel study didn’t find any problems, but FDA wants a closer look now that the dataset has grown.

As Eliquis Sales Lag, Bristol/Pfizer Take Action

The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts